Literature DB >> 17033325

Esophageal cancer.

Nimish Vakil1, Aboud Affi.   

Abstract

Despite advances in our knowledge of esophageal cancer, 50% of patients present with incurable disease, and the overall survival after diagnosis is poor. The incidence of esophageal adenocarcinoma of the distal esophagus is rising at a rapid rate in developed countries. Recent advances in the epidemiology of esophageal cancer offer insights into preventive strategies in patients who are at risk. New developments in diagnosis may help detect the disease at an early stage. New diagnostic modalities permit more accurate staging procedures and allow appropriate selection of therapy. New studies provide more information on multimodality therapy for esophageal cancer, and new endoscopic techniques allow resection of small lesions without surgery. New stent designs provide better palliation by providing tumor ingrowth. These developments in the treatment of esophageal cancer are the focus of this review.

Entities:  

Year:  2002        PMID: 17033325     DOI: 10.1097/00001574-200207000-00014

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  2 in total

1.  Induction of MUC5AC mucin by conjugated bile acids in the esophagus involves the phosphatidylinositol 3-kinase/protein kinase C/activator protein-1 pathway.

Authors:  Shumei Song; James C Byrd; Sushovan Guha; Kai-Feng Liu; Dimpy Koul; Robert S Bresalier
Journal:  Cancer       Date:  2010-12-14       Impact factor: 6.860

2.  Polyphenon E inhibits the growth of human Barrett's and aerodigestive adenocarcinoma cells by suppressing cyclin D1 expression.

Authors:  Shumei Song; Koyamangalath Krishnan; Kaifeng Liu; Robert S Bresalier
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.